Accelerating sales of Merck KGaA’s oral multiple sclerosis therapy Mavenclad helped the company ... MS but also the secondary progressive form of the disease. The other is Novartis’ recently ...

Europe’s CHMP top scientific committee gave a positive opinion for approval to cladribine, with the proposed trade name Mavenclad, for relapsing forms of MS with high disease activity.

Merck KGaA’s Mavenclad (cladribine) tablets have been recommended by ... The drug, which was previously only recommended by NICE as an option for highly active RRMS, a more severe form of the ...